2025-12-20 - Analysis Report
Here's a comprehensive analysis of Hims & Hers Health (HIMS) based on the provided data:

**1) Return Rate Comparison**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions directly to consumers.
*   **HIMS Cumulative Return:** 129.58%
*   **VOO (S&P 500) Cumulative Return:** 74.84%
*   **Divergence:** 68.3 (Relative Divergence: 37.9)
*   **Analysis:** HIMS has significantly outperformed the S&P 500 over the tracked period. The divergence of 68.3 indicates a substantial difference in cumulative returns. However, the relative divergence of 37.9 suggests that the current divergence is only in the lower percentile of the historical range, implying that the recent outperformance is not extreme relative to its own history.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0   | 1.5    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0 | 1.5    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1  | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0 | 5.5    |
| 2023-2025  | 134.0% | 80.8% | 69.0%  | 0.1   | 8.1    |

*   **CAGR:** The Compound Annual Growth Rate shows a volatile performance with significant negative growth in earlier periods and strong positive growth in the most recent periods (2022-2024 and 2023-2025).
*   **MDD:** The Maximum Drawdown remains consistently high, indicating significant risk and potential for substantial losses.
*   **Alpha:** Alpha measures the stock's performance relative to a benchmark.  The earlier periods show a negative Alpha, indicating underperformance. However, the recent periods (2022-2024 and 2023-2025) exhibit strong positive Alpha, suggesting significant outperformance.
*   **Beta:** Beta indicates the stock's volatility compared to the market. The Beta values are close to zero, suggesting the stock is less sensitive to market movements. This is unusual for a growth stock and could indicate it's influenced more by company-specific factors.
*   **Cap(B):** The market capitalization has increased significantly over time, reflecting the company's growth.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 35.56
*   **Previous Close:** 34.77
*   **Change:** 2.27%
*   **5-day SMA:** 35.68
*   **20-day SMA:** 37.36
*   **60-day SMA:** 44.56

*   **Analysis:** The stock is trading below its 20-day and 60-day Simple Moving Averages (SMAs), suggesting a short-term downtrend. However, the current price is slightly below the 5-day SMA, indicating some recent positive movement. The positive change from the previous close confirms this.

**3) Technical Indicators**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment)
*   **RSI (Relative Strength Index):** 44.60
*   **PPO (Percentage Price Oscillator):** 0.0229
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 1.1 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** 24.2%

*   **Analysis:**
    *   The MRI suggests a medium investment risk level.
    *   The RSI is below 50, indicating that the stock is not overbought.
    *   The PPO is slightly positive, suggesting some upward momentum.
    *   The Hybrid Signal is indicating a "Buy" recommendation.
    *   The recent increase in relative divergence supports a short-term upward trend.
    *   The expected return of 24.2% is attractive, indicating potential for future growth.
    *   The significant price change between the previous close and the current price highlights the volatility of the stock.

**4) Recent News & Significant Events**

*   **Negative Sentiment:** BofA Securities maintains an "Underperform" rating, citing growth concerns.
*   **Positive Sentiment:** Announcement of a $250 Million Share Repurchase Program.  This can boost the stock price.
*   **Valuation Discussion:** Articles discuss the stock's valuation after a recent pullback.
*   **Volatility:** Coverage of recent volatility and expansion efforts.
*   **Insider Selling:** Michael Chi sold shares.
*   **Growth & Profitability:** Hims & Hers is scaling technology-driven care as profitability evolves.

*   **Analysis:** The news headlines present a mixed picture. While the share repurchase program and articles highlighting growth potential are positive, the "Underperform" rating from BofA Securities and insider selling activity raise concerns. The focus on volatility reinforces the stock's risky nature.

**4-2) Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.93 (~Hold)
*   **Opinions:** 12
*   **Target Price:** Average: 44.67, High: 85.00, Low: 25.00
*   **Recent Rating Changes:** No recent changes provided.

*   **Analysis:**  The analyst consensus is "Hold," indicating a neutral outlook. The average target price of $44.67 suggests a potential upside from the current price.  However, the wide range between the high and low target prices ($85.00 and $25.00) reflects significant uncertainty among analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출   |
|------------|------|--------|
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

*   **Analysis:**
    *The provided data is inconsistent, as 2025-11-03 data is shown twice.
    *Revenue has generally increased over the last four quarters, indicating growth.
    *EPS has fluctuated, with a noticeable drop in the most recent quarter. This decline in EPS is a concern and warrants further investigation.

**6) Financial Information**

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.60B  | 73.80%        |
| 2025-06-30   | $0.54B  | 76.39%        |
| 2025-03-31   | $0.59B  | 73.50%        |
| 2024-12-31   | $0.48B  | 76.81%        |
| 2024-09-30   | $0.40B  | 79.16%        |

Capital and Profitability:

| Quarter      | Equity  | ROE    |
|--------------|---------|--------|
| 2025-09-30   | $0.58B  | 2.72%  |
| 2025-06-30   | $0.56B  | 7.55%  |
| 2025-03-31   | $0.55B  | 9.01%  |
| 2024-12-31   | $0.48B  | 5.46%  |
| 2024-09-30   | $0.44B  | 17.18% |

*   **Analysis:**
    *   Revenue shows a clear upward trend, reinforcing the growth narrative.
    *   Profit margins are consistently high, indicating strong pricing power and efficient operations.
    *   Equity has been increasing steadily, reflecting the company's growing net worth.
    *   ROE (Return on Equity) has fluctuated significantly but shows a sharp decline in the most recent quarter. The decline in ROE, coupled with the decrease in EPS, suggests potential profitability concerns.

**7) Comprehensive Analysis (Summary)**

Hims & Hers Health (HIMS) presents a mixed investment picture.

*   **Positives:**
    *   Significant outperformance compared to the S&P 500.
    *   Strong revenue growth and high profit margins.
    *   Positive Alpha in recent periods.
    *   Hybrid Signal indicating a "Buy" recommendation
    *   Share repurchase program announcement.
    *   High Expected Return (24.2%).

*   **Negatives:**
    *   High Maximum Drawdown (MDD) indicates significant risk.
    *   Recent decline in EPS and ROE raises concerns about profitability sustainability.
    *   BofA Securities' "Underperform" rating.
    *   Insider selling.
    *   Inconsistent data for EPS in the latest quarter
    *   The analyst consensus is "Hold," with a wide range of target prices.

*   **Conclusion:** HIMS appears to be a high-growth, high-risk stock. While it has demonstrated significant outperformance and exhibits strong revenue growth, the recent decline in profitability metrics and negative analyst sentiment warrant caution. Investors should carefully weigh the potential rewards against the inherent risks before investing in HIMS. Further investigation is needed to understand the reasons behind the EPS and ROE decline and the sustainability of future growth.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.